Summit Therapeutics Inc. Revenue From Government Grants
Summit Therapeutics Inc. (SMMT) reported Revenue From Government Grants of GBP 201.00 thousand for the 3-month period ending 2018-07-31, per its 6-K filed 2018-09-20.
Discontinued › Income Statement › Other Income
ifrs-full:RevenueFromGovernmentGrants · last filed 2018-09-20
- Summit Therapeutics Inc. revenue from government grants for the quarter ending 2018-07-31 was 201.00K GBP.
- Summit Therapeutics Inc. revenue from government grants for the quarter ending 2018-04-30 was 103.00K GBP.
- Summit Therapeutics Inc. revenue from government grants for the quarter ending 2017-07-31 was 0.00 GBP.
- Summit Therapeutics Inc. revenue from government grants for the quarter ending 2017-04-30 was 0.00 GBP.
| Period end | Revenue From Government Grants 3 month | Revenue From Government Grants 6 month | Revenue From Government Grants 12 month |
|---|---|---|---|
| 2018-07-31 | 201.00K GBP 6-K · filed 2018-09-20 | 304.00K GBP 6-K · filed 2018-09-20 | |
| 2018-04-30 | 103.00K GBP 6-K · filed 2018-06-05 | ||
| 2018-01-31 | 13.00K GBP 20-F · filed 2018-04-13 | ||
| 2017-07-31 | 0.00 GBP 6-K · filed 2018-09-20 | 0.00 GBP 6-K · filed 2018-09-20 | |
| 2017-04-30 | 0.00 GBP 6-K · filed 2018-06-05 | ||
| 2017-01-31 | 56.00K GBP 20-F · filed 2018-04-13 | ||
| 2016-01-31 | 645.00K GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |